This study is testing if adding **Herceptin Hylecta** or **Phesgo** to usual chemotherapy helps shrink tumors in patients with a type of cancer called **HER2 positive endometrial cancer**. Herceptin Hylecta and Phesgo are types of medicines that target specific cancer cells. They are given with chemotherapy drugs called **paclitaxel** and **carboplatin**. These drugs work together to stop cancer cells from growing and may help kill them. The study has three groups, and patients are randomly placed in one. Each group gets different combinations of the medicines. Treatments are given every three weeks for a set number of cycles. Patients are followed up for several years even after treatment ends.

• Study Length: Treatments every 3 weeks up to 1 year, with follow-ups every few months for 5 years.
• Visits: Regular visits for treatment and monitoring, including tests like heart and CT scans.
• Risks: Possible side effects include fatigue, nausea, and risk of infection; detailed monitoring for heart health and other side effects.